Naloxone intranasal - Amphastar
Alternative Names: REXTOVYTMLatest Information Update: 07 Mar 2025
At a glance
- Originator Amphastar Pharmaceuticals
- Class Antidotes; Behavioural disorder therapies; Benzofurans; Drug withdrawal therapies; Isoquinolines; Ketones; Laxatives; Morphinans; Small molecules
- Mechanism of Action Opioid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Opioid-related disorders
Most Recent Events
- 31 May 2024 Launched for Opioid-related disorders in USA (Intranasal)
- 06 Mar 2024 Amphastar Pharmaceuticals announces intention to launch naloxone intranasal for Opioid-related disorders in USA, in the first quarter of 2024
- 21 Feb 2017 Amphastar Pharmaceuticals receives complete response letter from the FDA for Naloxone intranasal in Opioid abuse